 |
Elan Corp ELN (news,
chart,
quote) - ELN July volatility Elevated into Phase 2 Data
ELN's & WYE's Bapineuzumab (Alzheimer's treatment) Phase 2 trail results are expected in Q2. ELN June option implied volatility is at 75, July is at 96 and October is at 80; above its 26-week average of 66 according to Track Data, suggesting larger price movement.
|
|
|
|
